

**Name:** Millennium HealthCare, Inc.

**Corporate Headquarters:** 68 South Service Road • Suite 100 • Melville, NY • 11747

**Website:** www.millenniumhcs.com

**Gulf South Region / Louisiana Division** (in progress): 1010 Roper Drive • Suite 4445 • Scott, LA • 70583

**Industry Group:** Health Care / Medical Services

**Gulf South Region / Mississippi Division** (in progress): 7640 Old Canton Road • Suite 6000 • Madison, MS • 39110

## Millennium HealthCare ... the Right Products ... in the Right Markets ... at the Right Time

### It all starts with the products.

To achieve success in today's rapidly growing – and rapidly changing – medical services sector, it is imperative for a company to have not only the right products and services, but that company must also be able to demonstrate the benefits of these offerings to the end-user patients, as well as to the physicians who serve them.

Millennium HealthCare, Inc. (Stock Symbol: **MHCC**) is one of those rare companies which has successfully positioned itself in the right place, with the right products, at the right time. It is for these reasons – along with the **Investment Considerations** listed below – that we have issued a "**Strong Buy**" Recommendation for MHCC.

### The Company:

Millennium HealthCare is a provider of (a) specialized physicians practice management services and (b) innovative medical equipment, with a proprietary line of revolutionary devices that focus on prevention and / or early detection. MHCC's products and services can provide immediate benefits to physicians as its devices are:

- **reimbursable** by most **insurance providers** and **Medicare**;
- **approved** by the **U.S. Food & Drug Administration (FDA)**.

These products provide physicians with timely and accurate diagnostic screening, and allows for more direct patient care, as well as new cash-flow streams, at a time when doctors are searching for new ways to generate revenues.

MHCC is headquartered in Melville, NY; and is currently in the process of tapping an entirely new markets through Primary Care Physicians (PCP's) in the Gulf South Region – the so-called "Heart Attack Belt" – with the opening of new MHCC offices in the burgeoning regional medical centers of Lafayette (Scott), LA and Jackson (Madison), MS.

### Lines of Business:

MHCC is primarily engaged in providing:

- management consulting to primary care physicians (PCP's) and their professional practices;
- business development services to physicians groups, clinics, labs, hospitals and other facilities;
- specialized administrative services (procedure coding, billing / collections, call / emergency management);
- as well as the sale, distribution (and training for) state-of-the-art medical devices that focus on vascular disorders, such as peripheral arterial disease of the lower extremities.

MHCC is dedicated to (what can often seem to be the mutually exclusive goal) of (1) improving patient care while simultaneously (2) enhancing healthcare practice efficiency, margins and profitability.

In addition to vascular medicine, the Company focuses on cardiology, oncology, general medicine and chronic pain management – with a focus on preventative care and early detection.

### Primary Products & Services:

MHCC's innovative product line and services include:

- **Lab Services** – The Company's full-service specialty medical laboratory provides everything from basic preventative screenings to the most innovative tests using cutting edge technology and instrumentation to ensure both accuracy and efficiency. The lab's complete list of services also include providing collection supplies, transportation services, express turn-around, and comprehensive on-line patient reporting.
- **UroVal** – A non-invasive product (requiring minimal time, effort and discomfort) which provides neurological insight into the health of S2-S4 pathways, which control urinary, fecal and sexual functions within the body.
- **VasoScan** – Provides early detection of arterial wall elasticity and determination of biological arterial age in less than five minutes. Non-operator dependent software monitors effectiveness of therapeutic intervention and monitors arterial wall response to lifestyle changes, helping reduce cardiovascular risk factors.
- **Oral CDx BrushTest™** – Clinically-proven, non-invasive test detects oral cancer with quick, easy, painless, and accurate detection of oral dysplasia, including HPV virus. Both physician's fees for performing the brush biopsies and lab fees for analyzing oral swabs are covered by most insurance carriers, as well as Medicare.
- **Derm CDx Brush Biopsy™** – Quick, painless, accurate test to diagnose Basal Cell Carcinoma; allows PCP's to incorporate this non-invasive test into the daily primary care routine, and also generate new revenue.

### Investment Considerations:

With this in mind, we have issued our "Strong Buy" Recommendation based on the following indicators:

- **Strategy** – MHCC has made a wise move to open two new sales / marketing / distribution offices – deep in the heart of the Gulf South "Heart-Attack Belt" – near Jackson, MS and Lafayette, LA regional medical centers, with additional plans to expand its reach throughout Mississippi, Louisiana, Alabama and Texas.
- **Management** – MHCC is in the process of recruiting a new Executive Management Team, which will bring with it deep contacts with the local (distribution) markets; extensive experience in the health care sector; and demonstrated expertise in the areas of corporate management, cost analysis and business restructuring.
- **Financial** – MHCC has recently reached settlements with major creditors / lenders on the majority of its old outstanding ("legacy") debt, and has institutional investors poised and ready to help capitalize its growth and organic (internal) expansion plans – as well as to fund strategic mergers and acquisitions (M&A's).
- **Shareholders** – Moreover, MHCC is pro-actively addressing the concerns of its equity owners by putting in place a comprehensive Capital Plan that should enable the Company to significantly enhance shareholder value and meet all of the requirements for an "up-listing" onto the NASDAQ National Stock Market.

**LJR Capital Management** is an independent business consulting firm which works with investment bankers to provide small-to-medium sized companies with access to capital.

The firm is spearheaded by **Lou Resweber**, who has more than 30 years of experience in the areas of cost analysis, corporate restructurings, and business turnarounds.

In addition to his role at LJR Capital, he also serves as Chief Operating Officer of **ESP PetroChemicals, Inc.**, a provider of specialty chemicals to the oil and gas industry, and as a member of the Boards of a number of other companies.

### Capital Markets Experience:

Prior to founding LJR Capital Management, he served as Chairman, President & CEO of **Pelican Security Network / Pelican Finance Company**, which he initially capitalized and built from a "start-up" operation into the nation's 36th largest electronic security and financial services provider – placing it among the top 1% of an industry populated by more than 14,000 licensed participants nationally. Decimated by Hurricane Katrina in 2005, Pelican was successfully re-built and ultimately sold to **Vector Security** of Pittsburgh, PA in 2015.

Before Pelican, Resweber was Chairman of the Board of **Westmark Group Holdings** (NASDAQ: WGH), which he transformed from a small local lender into a nationwide financial services provider. And as President & CEO of **Network Long Distance / Network Acquisition** (NASDAQ: NTWK), he helped grow that company from \$4 million to \$120 million in annual sales through 17 successful mergers and acquisitions (M&A).

Previously, as Senior Vice President of **United Companies Financial** (NYSE: UC), Resweber helped this organization gain unprecedented access to capital, eventually moving the company from NASDAQ to the NYSE, and then leading UC's efforts to push its stock price from \$16 to \$132 per share – a 725% rise – making it the top growth stock in any industry at that time.

### Early Career:

Resweber began his career in the energy industry, serving on the management team of **Celeron Oil & Gas** (NYSE: CEL), which was active in exploration, production, transportation, refining, marketing and distribution. He also represented Celeron in its merger with **Goodyear Tire** (NYSE: GT); and in its efforts to build the nation's longest oil transportation system (at that time), the **All American Pipeline** (now Plains Resources), a unique California-to-Texas underground oil transportation conduit more than twice as long as the famous **Trans-Alaska Pipeline**.

Resweber later served as Vice President of **Entex Gas** (now CenterPoint Energy) in Houston, which then merged with **NorAm Energy / ArkLa Gas** (now NRG / Reliant Energy) to form the nation's fourth largest natural gas distributor. Resweber went on to lead the spin-off and initial public offering (IPO) of **Arkla Exploration** (NYSE: ARK) as an independent operating entity on the New York Stock Exchange. And as Vice President of **Hill & Knowlton International**, he represented a number of other major industry participants including **Exxon / Mobil Oil** (NYSE: XOM) and **Cabot Oil & Gas** (NYSE: COG).

Ratings Issued: **Strong Buy** Buy Hold Sell

This "**Strong Buy**" Recommendation is issued by **LJR Capital Management, LLC** for general information purposes only. LJR Capital Management is not a registered broker / dealer. Moreover, LJR Capital Management is neither licensed nor authorized to buy, sell and / or trade securities. The information and opinions included in this document constitute neither an offer to sell – nor a solicitation to buy – any securities or financial instruments. In order to fully understand all of the implications and risks of such an investment, potential investors are advised to contact a registered broker, and to review all public filings related to the above-named company. It should be duly noted that no regulatory agency has opined on the merits, approved, authorized, or endorsed this recommendation. Any representation to the contrary is completely and entirely unintended.

This material contains forward-looking statements within the meaning of the Private Securities expectations, as of the date hereof, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the development of the Company's medical devices business and the future of the medical device industry. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various the Securities and Exchange Commission (www.sec.gov). The Company's further development is highly dependent on futur is highly dependent on future medical and research developments an market acceptance, which is outside its control.